CDT Equity Inc. CDT

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today notes the announcement from Sarborg Limited regarding the filing of new intellectual property applying quantum sampling to disease biology and drug discovery. CDT holds 1,290 shares in Sarborg, representing 22.7% of the issued share capital. Sarborg’s latest capital raise was at $125,000 per share, implying a fully diluted valuation of approximately $709 mil

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-25 reverse stock split of the Company’s common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios. The reverse stock split w

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a partnership with QIMA Life Sciences, a world leading preclinical dermatology CRO, to explore the potential of several of CDT’s assets in autoimmune skin diseases. CDT plans to leverage QIMA’s unique access to human skin from both healthy donors and patients. The use of patient tissue offers the most clinically relevant d

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 10, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today notes the announcement from Sarborg Limited regarding the successful application of its patented Signature Intelligence and quantum computing models to mental health and neuropsychiatric drug discovery. Mental health represents a significant global healthcare opportunity, with more than 1 billion people globally1 living with a mental disorder and depression

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that, following the recent issuance of shares and the exercise of pre-funded warrants, the Company had 13,693,866 shares of Common Stock issued and outstanding as of August 31, 2026. Based on the closing price of CDT’s Common Stock on August 31, 2026, the Company had a market capitalisation of approximately $23.0 million. CDT’s stockholders’ equity

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 01, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced the appointment of James Bligh, co-founder of Conduit Pharmaceuticals Limited (now CDT), as Chief Executive Officer. Mr. Bligh brings extensive public-markets, corporate finance and transaction experience to the role and will lead the Company as it enters its next phase of growth and value creation. Dr. Andrew Regan has been appointed as CEO of Sar

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that new solid forms and alternative crystal structures of its existing drug compounds, show enhanced physical property advantages, including improved stability, solubility, manufacturability, over existing forms of these compounds. These solid forms are patent-protected under the Company’s Substance of Matter IP and could support new formulations

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a SAFE note with Pep'd Inc. (“Pep'd”), a US-based peptide company, expanding CDT's exposure to the growing US peptide market (the “Transaction”). Upon Pep’d closing an Equity Financing, this SAFE will automatically convert into a number of shares of Safe Preferred Stock, depending on the Pep’d Capitalization at that time an

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that it has entered into a strategic transaction to increase its equity stake in Sarborg Limited (“Sarborg”), an agentic AI signature intelligence business operating across multiple industrial sectors, to 22.7% through the issuance of pre-funded warrants to purchase up to 12,131,770 shares of the Company’s common stock, subject to shareholder approv

NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the filing of a new patent application covering a large set of field-deployable, two-component combination interventions for sugarcane cultivation, generated through Sarborg's quantum-enabled PRISM platform. According to Sarborg, the filing organizes its claimed combinations around six distinct applicatio

NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the expansion of its Signature Intelligence platform into quantum-assisted coformer selection through SarborgQ, the Company's dedicated quantum computing division. According to Sarborg, the initiative combines the Company's proprietary datasets, agentic AI architecture and emerging quantum computing capab

NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding its recent fundraise from a New York-based private investment fund. According to Sarborg, the subscription was completed at a consideration per share of $125,000, implying a fully diluted valuation of approximately $638.3 million. The proceeds will be used to support the launch and development of SarborgQ

NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has re-structured its debt, agreeing to pay off all outstanding amounts due under its Loan Notes with Alliance Global Partners (“A.G.P.”) and Ascent Partners, and entering into a new Loan Agreement with JJ Astor for up to $1,460,000. The A.G.P. Convertible Loan Note originally entered into in December 2024, had a principal amount of $5,737,

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that the Company received a written notice (“Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2026 indicating that the Company did not timely file its Quarterly Report on Form 10-Q for the three-month period ended March 31, 2026 (the “Form 10-Q”), as required for continued listing on The

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 27, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that the patent covering the use of AZD5904 in male infertility has now been granted in Canada, completing the approval of this patent in all key pharmaceutical target markets. CDT believes that the extensive geographical coverage of this patent combined with its more recent composition of matter application provides a strong IP position for develop